Terms: = Lung cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Treatment
335 results:
1. Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
Singh S; Saxena S; Sharma H; Paudel KR; Chakraborty A; MacLoughlin R; Oliver BG; Gupta G; Negi P; Singh SK; Dua K
Pathol Res Pract; 2024 Apr; 256():155222. PubMed ID: 38452582
[TBL] [Abstract] [Full Text] [Related]
2. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
Baranyi M; Molnár E; Hegedűs L; Gábriel Z; Petényi FG; Bordás F; Léner V; Ranđelović I; Cserepes M; Tóvári J; Hegedűs B; Tímár J
Br J Cancer; 2024 Apr; 130(6):1059-1072. PubMed ID: 38278976
[TBL] [Abstract] [Full Text] [Related]
3. The diagnosis and treatment for primary cardiac angiosarcoma with n-ras gene mutation and MSI-L: A case report and review of the literature.
Sun J; Wei T; Sun B; Su J; Liu H; Wang D; Li X
Medicine (Baltimore); 2023 Dec; 102(51):e36682. PubMed ID: 38134104
[TBL] [Abstract] [Full Text] [Related]
4. Runx3 Restoration Regresses k-ras-Activated Mouse lung cancers and Inhibits Recurrence.
Lee JY; Lee JW; Park TG; Han SH; Yoo SY; Jung KM; Kim DM; Lee OJ; Kim D; Chi XZ; Kim EG; Lee YS; Bae SC
Cells; 2023 Oct; 12(20):. PubMed ID: 37887282
[TBL] [Abstract] [Full Text] [Related]
5. The inhibition of pancreatic cancer progression by k-ras-overexpressing mesenchymal stem cell-derived secretomes.
Huo Q; Li K; Sun X; Zhuang A; Minami K; Tamari K; Ogawa K; Fishel ML; Li BY; Yokota H
Sci Rep; 2023 Sep; 13(1):15036. PubMed ID: 37699930
[TBL] [Abstract] [Full Text] [Related]
6. Small molecular inhibitors for KRAS-mutant cancers.
Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
[TBL] [Abstract] [Full Text] [Related]
7. Development and evaluation of a customized checklist to assess the quality control of disease registry systems of Tehran, the capital of Iran in 2021.
Barzin M; Sabbaghi H; Kamfar S; Seifi A; Hajipour M; Siri FH; Mir-Moeini E; Gharajeh A; Ferdosifard N; Panahi M; Nazari SSH; Atatalab FF; Etemad K
BMC Health Serv Res; 2023 Jul; 23(1):726. PubMed ID: 37403074
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of
Lastraioli E; Bettiol A; Iorio J; Limatola E; Checcacci D; Parisi E; Bianchi C; Arcangeli A; Iannopollo M; Di Costanzo F; Di Lieto M
Cells; 2023 May; 12(11):. PubMed ID: 37296579
[TBL] [Abstract] [Full Text] [Related]
9. Determining the mechanism of action of the Qishan formula against lung adenocarcinoma by integration of network pharmacology, molecular docking, and proteomics.
Geng X; Chi W; Lin X; Niu Z; Jiang Q; Sui Y; Jiang J
Medicine (Baltimore); 2023 Mar; 102(13):e33384. PubMed ID: 37000102
[TBL] [Abstract] [Full Text] [Related]
10. Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.
Tawfeeq N; Lazarte JMS; Jin Y; Gregory MD; Lamango NS
Oncotarget; 2023 Mar; 14():243-257. PubMed ID: 36961909
[TBL] [Abstract] [Full Text] [Related]
11. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors.
Anthiya S; Öztürk SC; Yanik H; Tavukcuoglu E; Şahin A; Datta D; Charisse K; Álvarez DM; Loza MI; Calvo A; Sulheim E; Loevenich S; Klinkenberg G; Schmid R; Manoharan M; Esendağlı G; Alonso MJ
J Control Release; 2023 May; 357():67-83. PubMed ID: 36921725
[TBL] [Abstract] [Full Text] [Related]
12. A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell lung cancer Cell Lines through MAPK and P70S6K Inhibition.
Barrios-Bernal P; Lucio-Lozada J; Ramos-Ramírez M; Hernández-Pedro N; Arrieta O
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901764
[TBL] [Abstract] [Full Text] [Related]
13. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
[TBL] [Abstract] [Full Text] [Related]
14. Mutational Damages in Malignant lung Tumors.
Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Dushimova Z; Vasilieva T
Asian Pac J Cancer Prev; 2023 Feb; 24(2):709-716. PubMed ID: 36853323
[TBL] [Abstract] [Full Text] [Related]
15. Role of a Mixture of Polyphenol Compounds Released after Blueberry Fermentation in Chemoprevention of Mammary Carcinoma: In Vivo Involvement of miR-145.
Mallet JF; Shahbazi R; Alsadi N; Saleem A; Sobiesiak A; Arnason JT; Matar C
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835085
[TBL] [Abstract] [Full Text] [Related]
16. Mutated hras Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck cancer.
Jagadeeshan S; Prasad M; Badarni M; Ben-Lulu T; Liju VB; Mathukkada S; Saunders C; Shnerb AB; Zorea J; Yegodayev KM; Wainer M; Vtorov L; Allon I; Cohen O; Gausdal G; Friedmann-Morvinski D; Cheong SC; Ho AL; Rosenberg AJ; Kessler L; Burrows F; Kong D; Grandis JR; Gutkind JS; Elkabets M
Cancer Res; 2023 Apr; 83(7):1031-1047. PubMed ID: 36753744
[TBL] [Abstract] [Full Text] [Related]
17. Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in k-ras-driven cancer.
Glorieux C; Xia X; You X; Wang Z; Han Y; Yang J; Noppe G; Meester C; Ling J; Robert A; Zhang H; Li SP; Wang H; Chiao PJ; Zhang L; Li X; Huang P
J Adv Res; 2022 Sep; 40():109-124. PubMed ID: 36100320
[TBL] [Abstract] [Full Text] [Related]
18. hras Q61L Mutation as a Possible Target for Non-Small Cell lung cancer: Case Series and Review of Literature.
Mathiot L; Herbreteau G; Robin S; Fenat C; Bennouna J; Blanquart C; Denis M; Pons-Tostivint E
Curr Oncol; 2022 May; 29(5):3748-3758. PubMed ID: 35621690
[TBL] [Abstract] [Full Text] [Related]
19. Differential proteome and functional analysis of NSCLC cell lines in response to Tualang honey treatment.
Amran N; Abdul-Rahman PS
J Ethnopharmacol; 2022 Jul; 293():115264. PubMed ID: 35398242
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy of siRNA-loaded nanoparticles in the treatment of k-ras mutant lung cancer
Gencer A; Baysal I; Nemutlu E; Yabanoglu-Ciftci S; Arica B
J Microencapsul; 2022 May; 39(3):261-275. PubMed ID: 35356841
[TBL] [Abstract] [Full Text] [Related]
[Next]
